Our Mission:
To develop drugs that
target components of the ubiquitin system, based on our expanding
proprietary knowledge.
Our Vision:
Proteologics
aspires to become a fully integrated pharmaceutical company and a leader
in the emerging field of the ubiquitin-related drugs.
Company
Profile:
From Target Discovery to Drug
Development
Proteologics identifies new correlations between
ubiquitin pathway components and pathological conditions. Once specific
E3 targets are discovered and validated, we proceed to establishing
proprietary technologies for the accelerated hit-to-lead drug discovery
process. Proteologics' recognized competencies are built through a
number of internal programs and partnerships, including a strategic
R&D collaboration with Teva Pharmaceutical Industries Ltd.
Company Background:
Proteologics Inc. was founded in
1999 and is a private corporation registered in Delaware, USA. Proteologics Inc.
R&D is performed at its wholly owned Israeli subsidiary,
Proteologics Ltd.